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ABSTRACT
Transdermal spray offers numerous advantages over the other conventional transdermal drug delivery forms such as gel, 
ointment and patches, in terms of its cosmeceutical appearance, ready availability for application, flexibility in dosage 
design, less occurrence of skin irritation and faster drying rate from the application site due to the use of volatile solvent. 
However, compared to other transdermal drug delivery dosage forms, transdermal spray has the least and limited num-
ber of products approved for marketing. Among the drugs are, Evamist®, an estradiol formulation approved in 2007 by 
the FDA followed by Axiron® a non-spray solution to treat low testosterone in men and Recuvyra®, a pain reliever solution 
indicated for dogs. This review article focuses current status on the formulation and evaluation of transdermal spray in 
the background of the role and effects of its composition specially the selection of drugs, volatile solvents, penetration 
enhancers and film forming polymer, etc. The limitation of transdermal spray highlighted in this review is the concern of 
its use, especially, the third party exposure particularly for endocrinology indication. Moreover, transdermal spray is also 
restricted in drugs with large doses due to the limited diffusivity into the skin. The difficulty of exploiting hydrophilic drugs 
like peptides, macromolecules and new genetic treatments using DNA or small-interfering RNA (siRNA) into transdermal 
spray formulations is also a limitation that needs to be explored in depth.
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INTRODUCTION 
Transdermal drug delivery (TDD) is one of the alternative 
modes of drug administration preferred over oral and injec-
tions. This is due to its distinct advantages such as avoidance 
of first pass metabolism relating to oral administration, provi-
sion of steady state drug-plasma concentration, improvement 
of patient adherence, prevention of potential gastrointestinal 
(GI) adverse effects and reduction of medical waste of hypo-
dermic needles in low resource settings [1,2]. The skin pro-
vides a large surface area suitable for absorption and the non-
invasive procedure for the transdermal drug system such as a 
patch that enables a continuous intervention with the applied 
medication [3]. The amount of drug delivered through the 
skin and the obtained therapeutic effect depends on the abil-
ity of the drug to permeate through the skin. The permeation 
of the drug into the skin is restricted by the stratum corneum 
(SC), the outermost layer of the skin, which is surrounded by 
a lipid region [4]. Numerous approaches like iontophoresis, 
sonophoresis, electroporation, use of chemical permeation 
enhancers (PE), microniddle, and the use of lipid vesicles have 
been studied for the last 30 years to break the barrier proper-
ties of SC and some of them have produced commercial suc-
cess [5,6]. 
The development of the transdermal delivery system can be 
classified into three generations. The first generation consists 
of low-molecular weight, lipophilic, and low dose drugs. The 
second generation uses permeation enhancement methods 
such as conventional chemical PEs, iontophoresis, and non-
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cavitational ultrasound in order to increase the drug perme-
ability through the SC. The selection of PE was carried out 
carefully according to several criteria; i) enhanced permeation 
ability without causing permanent disruption in the structure 
of the stratum corneum, ii) ability to enhance transdermal flux 
in maximum amount iii) permeation ability without causing 
any injury to the deeper tissues. The third generation focuses 
more on giving the effects on the stratum corneum by incor-
porating microneedles, thermal ablation, microdermabrasion, 
electroporation and cavitational ultrasound [7]. 
Over the years, transdermal patch has emerged as the main 
form of TDD [8]. However, one of the main concerns in using 
a patch form is the high level of residual drug in the patch 
after wear time, which leads to unintended drug exposure 
and intentional drug abuse [8]. The patch is also associated 
with the skin hypersensitivity reaction, for example, redness 
and irritation, blistering and tattooing [9]. Large scale com-
mercial production of the patches involves a certain degree of 
complexity, especially the scale-up procedures of multi-com-
ponents patches. Occasionally, the problems of formulation 
stability and crystallization of drug molecules during long time 
storage have been evidenced to the marketed products [10]. 
Due to these particular reasons, gel system are being actively 
explored and developed as the alternative to patches. The gel 
system demonstrates almost equivalent clinical performance 
to the patch system, but with reduced skin irritation and im-
proved patient compliance [11]. Semisolid dosage forms like 
gel, cream, ointment and paste could be easily rubbed off by 
the clothing and during routine daily activities. Gel needs to 
be applied over a large surface on the skin and the occasional 
transfer to a third party, especially for endocrinic indications is 
a major concern. In case of fungal infection of the skin, semi-
solid dosage forms should not be applied over the infected 
area with fingers. It might have a chance of cross-infection to 
other body parts. 
Transdermal spray (TS) is believed to have more superiority 
over the conventional TDD systems in the light of its safety, 
and tolerability [8]. As compared to conventional TDD systems 
(patches, gel, and ointment), TS is readily available for appli-
cation, provides flexible drug dosage delivery, and reduces 
the occurrence of skin irritation and the patients need not to 
clean their hands after the application [8, 12,13]. Because of 
volatile solvent content, TS system creates a fast drying and 
non-occlusive layer on the skin after its application and helps 
rapid drug permeation through the skin [11,14]. 
TS offers many benefits and has a wide potential to be devel-
oped as the preferred TDD over gels, patches and ointment in 
order to avoid skin irritations and improved patients’ compli-
ance. However, its efficacy is majorly dependent on the selec-
tion of appropriate excipients that will help improve the trans-
dermal flux of the drug. So, the goal of this review article is 
to familiarize the readers about the formulation aspects of TS 
under the purview of latest developments in this field.
History of Transdermal Drug Delivery
Human skin has been exploited as the route of drug delivery 
since ancient time. Medications applied on it can exert local 
or systemic action depending on their designations and their 
inherent properties coming out of their composition. Trans-
dermal drug delivery system is defined as, “A drug loaded into 
any vehicle (e.g., patch, gel, or spray) applied to the skin for 
systemic action. In addition, the iontophoretic systems includ-
ed in it irrespective of their systemic or local action” [2]. On 
the other hand, topical delivery is limited to the application of 
dosage form to the body surfaces such as the skin or mucous 
membranes for anti-infective of cosmetic purpose.
In 1979, the first transdermal product approved by US-FDA 
was a scopolamine patch that delivers the drug systemically 
for three days to treat motion sickness. This was followed 
by the development of nicotine patch a decade later that 
emerged as the first blockbuster transdermal product. This 
achievement had raised the image of transdermal product in 
the health care field and in the eyes of the medical practitio-
ners as well as the patient population [7]. 
However, for the last three decades, the formulation scien-
tists are searching for other ways and developing novel tech-
nologies to overcome the constrain of crossing the SC barrier. 
Passive diffusion is the most dominant mechanism of drug 
transport through the skin. Three possible pathways for trans-
dermal delivery have been reported. A drug is transported 
through the transappendageal route such as hair follicles and 
sweat glands (1) (shunt pathway), transcellular or intracellu-
lar transport through the corneocytes (2A) and intercellular 
transport via the lipid matrix (2B) as shown in Figure 1 [15]. In 
transcellular or intracellular pathway the drug crosses the SC 
straight way through the different layers of the SC by repeated 
partition through the cornified cells, the extracellular lipid bi-
layers, viable epidermis and papillary layer of the dermis. In 
intercellular pathway the drug always remains within the lipid 
domains and transports through a lengthy and highly complex 
pathway attributed by repeated turns and bends as shown in 
Figure 1 (2B). Various PEs influence the drug transport via this 
route by temporarily modifying the structural features of the 
lipid bilayer. In Shunt pathway the drug permeates through 
the SC via hair follicles or sweat glands. However, considering 
its lower diffusional area (0.1% of the total skin area), the drug 
transport contribution through this route is considered very 
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negligible. Ions and large polar molecules have been reported 
to permeate through this route [15]. The transcellular route 
is preferred by hydrophilic substances. In general, molecules 
with amphoteric chemical properties are thought to be able 
to penetrate the best. However, drugs must have certain crite-
ria which are small molecular weight (below 500Da), moder-
ate lipophilicity (logP ideally around 2-3) and lastly, good solu-
bility both in water and oil so that they are able to permeate 
the lipophilic stratum corneum and hydrophilic compartment 
of the systemic circulation [6, 8]. With the aid of many novel 
approaches and technologies mentioned earlier, the drug de-
livery through the skin has been enhanced. These inventions 
have broadened the spectrum for the drug selection instead 
of being restricted to the criteria set due to the conventional 
passive diffusion limitations.
Figure 1: Drug transport pathways through the stratum corneum. Re-
printed from [15].
Drug Delivery Mechanism of TS
TS consists of a volatile solvent system which creates a rapidly 
drying film when sprayed onto the skin [8, 12]. Metered dose 
transdermal spray (MDTS) system ensures the required volu-
metric delivery of the dose from its primary packaging mate-
rial. During application, the volatile solvent will carry the drug 
into the upper layers of the skin and then evaporates. This ac-
tion leaves a high concentration of the drug in the skin which 
acts as the drug reservoir to release the drug continuously 
and slowly into the circulation [8]. Once the volatile solvent 
evaporates from the SC layers, it leaves a thin-uniform film of 
the drug that has a high thermodynamic activity and perme-
ates into the skin rapidly [16]. The Equation below provides 
the explanation of drug permeation of a TS through the skin.  
Where, Msat = SC saturation dose, Csat = SC saturation concen-
tration, h = thickness of the SC.
M
sat
 depends on the evaporation rate of the volatile solvent 
and the depth of penetration of the solvent. If the dose is 
higher than M
sat
, the excess drug will remain deposited on the 
surface of the SC. It will maintain the saturation of the drug 
within the SC as the drug slowly permeates into the deeper 
skin layer and enters into systemic circulation. The drug de-
livered into the skin then act as a depot for the release of the 
drug into the deeper skin layer.
Transdermal Spray Formulation Components
Focusing on the components of TS formulation is the main 
part of product development. The formulation components 
are, but limited to, drug, volatile solvents, PEs, and film form-
ing polymers (FFP) [4, 14].
Drug molecule in a TS formulation
Molecular weight and lipophilicity of the drug are two essen-
tial components for drug selection in a TS formulation [17]. 
Table 1 represents the required criteria for a drug molecule to 
be fit for any TS formulation [3].
Table 1: Considerations of drug molecules for TS formulationa.
Parameter Limit
Aqueous solubility > 1mg ml-1
Lipophilicity 10 < K
O/W 
< 1000
Molecular weight < 500 Da
Melting point < 200 ̊C
pH of saturated aqueous solution pH 5-9
Dose deliverable < 10 mg day-1
aReproduced from [3].
All of the above factors are considered to be suitable and ideal 
for a drug intended to overcome the SC barrier of the skin. 
Fick’s law of diffusion describes the permeation of the drug 
into the stratum corneum as shown in equation 2. These vari-
ables are the important parameters in optimizing the trans-
dermal bioavailability.
Where, Jss = steady state flux (mg/cm
2) across a membrane, 
h = membrane thickness in cm, D = drug diffusivity through 
the SC (cm2/hr), Ksc/veh = partition coefficient of the drug in the 
SC and vehicle, Cveh = drug concentration in the vehicle (mg/
ml), Kp = formulation-dependent permeability coefficient of 
the drug.
From the equation 2, it can be derived that transdermal flux 
can be modified mainly by three parameters: D, K
sc/veh 
and 
C
veh. 
The structure of lipoidal SC itself is supported by aque-
ous epidermal layer and this affects the diffusion process. 
Msat = Csat × h ……….. (1)
10
Jss = D.Ksc/veh. Cveh = Kp. Cveh ………. (2)
 h
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Hence, K
sc/veh 
value of the drug must favour both transport 
into and out of the SC. Higher C
veh 
value may increase the 
drugs transfer into the skin. Therefore, the solvent must have 
a sufficiently high holding capacity and at the same time able 
to aid the transfer process of the drug across the SC [18].
Penetration Enhancer/s
Penetration enhancers (PEs) are substances used in the TS 
formulation in order to increase the transdermal flux of the 
drugs [19-21]. PE reduces the binding of the drug to the skin 
and help to deliver the drug across the skin [22]. PE acts by 
disrupting the SC layer to provide the pathway for the drugs 
or by increasing the partitioning into the skin and the thermo-
dynamic activity of the drug [7, 23]. Ethanol and propylene 
glycol are two examples of PEs that can be additionally used 
as solvent/vehicle for TS formulations [24, 25]. Water, hydro-
carbons, acids, amines, amides, esters, surfactants, terpenes, 
terpenoids, essential oils, camphor, menthol, sulfoxides and 
lipids have been reported as PEs by many researchers [26, 27]. 
However, an ideal PE should have the following characteristics 
[28]: 
• It should be pharmacologically and chemically inert. 
• It should be chemically stable.
• It should be transparent and generally not volatile in 
nature.
• It should give reversible effect on the skin properties 
after its use.
• It should be compatible with the components in the 
formulation and the skin.
• It should not cause any irritation, sensitization, 
phototoxicity and comedogenicity.
• It should be cosmetically acceptable, odorless, tasteless 
and colorless.
• Its solubility parameter should be suitable for the 
formulation and skin.
The solubility of a drug in PE has an important role in influenc-
ing the amount of transdermal flux. It is hypothesized that PE 
acts as a vehicle and help increase drug transport through the 
SC. In fact, the more the drug is solubilized in the vehicle, the 
higher transdermal flux will be reached [29]. Accordingly, dur-
ing development of dexketoprofen TS formulation, Lu et al. 
[14] recorded the solubility of the drug in PE-cum-vehicle in 
the order of propylene glycol (PG) > isopropyl myristate (IPM) 
> lauryl lactate (LA) > azone (AZO). However, the ex vivo trans-
dermal flux was found to be the maximum for LA and mini-
mum for PG (Figure 2). The lowest transdermal flux in case 
of PG has been observed as its inability to form a drug reser-
voir as it carries the drug along with it during drug transport 
through the SC [14,30]. Interestingly, blank formulation (con-
taining alcohol as volatile solvent, but no PE) provided much 
higher amount of transdermal flux of the drug as compared 
to the group containing pure drug. This might be due to the 
increased thermodynamic energy of the drug after the evapo-
ration of alcohol. Additionally, ethanol might have provided its 
permeation enhancement activity [31].
Figure 2: Percutaneous permeation profiles of dexketoprofen MTDS con-
taining different penetration enhancers (mean ± SD; 𝑛 =3). Reprinted
from [14].
Volatile Solvents 
TS comprises volatile and non-volatile solvents. Volatile sol-
vents are classified as the solvents with vapor pressure higher 
than 35mm Hg when the body temperature is 32°C while non-
volatile solvents are those with vapor pressure below 10 mm 
Hg at the same body temperature [32]. Volatile solvent evapo-
rates after a short period of time, causing an increase in the 
thermodynamic activity of the drug. Prior to that, the solvent 
carries the drug into the SC layers, an effect called the solvent-
drag [8]. To some extent solvent contributes to the perme-
ation of the drug across the SC. That is why solvent selection 
is also important to optimize the drug delivery. The selected 
solvent should facilitate the transfer of the drug and have a 
high drug holding capacity [3]. 
In most of the TS formulations, alcohols such as alkenols, al-
kanols, polyglycols, glycols, and glycerols are used as volatile 
solvents. This group can also act as the penetration enhancers 
in improving transdermal flux of drugs [26]. Alcohols enhance 
the drug delivery into the skin by several mechanisms such as 
increasing the thermodynamic activity of the drug, solvent-
drag effect, extraction of lipids and proteins and swelling of 
the SC layers [33]. Bakshi et al. [12] reported that preformula-
tion studies of solvent system for a TS formulation with oxybu-
tynin. Ethanol: acetone: methylal with a ratio of 2:1:2 respec-
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tively, resulted desired spray patterns and high dispersibility 
of the polymers. According to Patel et al. [16], a combination 
of acetone with alcohol at 1:1 gives a faster film formation for 
the TS formulation. This finding was supported by Paradkar et 
al. [34] where the said combination of acetone and alcohol 
form a film layer in less than 5 minutes and the active ingre-
dients and film forming polymer (FFP) have good solubility in 
the vehicle. Fast drying film is preferred as to avoid the loss of 
drug through draining or removal of the drug by transferring 
to other surfaces [16].
Film Forming Polymers
Film forming polymer (FFP) is associated with an occlusion ef-
fect on the skin. The increasing influx of drugs into the skin 
due to the occlusion effect could be attributed to the follow-
ing factors [8]: 
• Higher fluidity in intercellular lipid of the SC
• Changes in the polarity of the intercellular lipid 
The dissolution of the excess drug on the surface of the skin  
Eudragit, acrylic polymer, polyvinyl pyrrolidone, ethyl cel-
lulose, etc. are widely used as FFPs in TS formulations [27, 
34]. There are few evidences where the incorporation of FFP 
can increase the transdermal flux of the drugs. Lu et al. [35] 
observed the above mentioned condition in five testoster-
one formulations, each containing different FFP. The results 
showed following trends in terms of transdermal flux: Plas-
done S630>Eudragit EPO>PVP K30>Eudragit RL. The trans-
dermal profiles of formulations containing each of these FFPs 
were higher compared to the control group which did not con-
tain any FFP (Figure 3). This was attributed to the preventive 
role of the polymer in crystallization of the drugs.
Figure 3: Percutaneous permeation profiles of testosterone MTDS formu-
lations containing different film forming polymers. Reprinted from [35].
Interestingly, the same research group reported a declin-
ing level of transdermal flux compared to control group for 
dexketoprofen TS formulation as shown in Figure 4 [14]. It was 
hypothesized that FFP inhibits the penetration of the drug into 
the skin due to the different drug composition and the incom-
patibility of the drug with the type or concentration of FFPs 
in the formulations. That’s why, there is a need for further 
discussion of the effect of FFP on occlusion to differentiate it 
from the role of solvent groups.
Figure 4: Percutaneous permeation profiles of MTDS of dexketoprofen 
containing different film forming polymers. Reprinted from [14].
Apart from the permeation enhancing effect, FFP has an im-
portant role in improving the uniformity of the spray pattern 
[16]. It is also responsible for reducing the drying time of the 
film layer [12, 14]. Other than that, FFPs are associated with 
the ability to inhibit the crystallization of the drugs as reported 
by many researchers [35, 36]. An ideal film forming polymer 
solution should have low viscosity, short drying time (less 
than 5 minutes) after application and cosmetically attractive. 
It should produce a flexible film without any sign of cracks or 
flakes and the film should be completely water washable after 
its use [37]. These FFPs should be well tolerated by the skin 
without any kind of compatibility issue.
Characterizations of the TS Formulations
Developed TS formulations are characterized by various quan-
titative and qualitative parameters such as viscosity and pH 
of the formulations, drying time, stickiness, appearance and 
integrity of skin and water washability, drug content, in vitro 
drug release, spray pattern and spray angle, average weight 
per dose, effectiveness of pump seal, stability study etc. [12]. 
Evaporation time is measured to check the time required to 
form a dried film. It is determined by measuring the time re-
quired to dry the film when sprayed onto a white paper [12]. 
Spray pattern testing is done to have an idea about the droplet 
sizes of the sprays. It is checked by measuring the sizes of the 
colored droplets deposited onto a white paper sprayed from 
a distance of about 2.5 to 3.0 cm. Formulation is colored with 
1% methyl orange for easy visualization of the droplets [34]. 
Spray angle is measured to check the distribution/spread of 
the formulation onto the application site. This is carried out 
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by the previous experiment (spray pattern) with the same col-
ored formulation where the white paper is placed horizontally 
at a distance of 15 cm from the nozzle. The radius of the circle 
formed on the paper is recorded and Spray angle is calculated 
from equation 3.
Spray angle (θ) = tan-1 (h/r) ”................3
Where, h is the distance of paper from the nozzle, and r is 
the average radius of the circle [27].
To check the effectiveness of the pump seal, or otherwise 
said, to ensure the container free of any leak, the filled con-
tainers are positioned up right at 300 and allowed to keep for 
3 days before checking any difference in the filled weight [12]. 
In vitro drug release and ex vivo skin permeation studies of 
the TS formulation are conducted by Franz diffusion cell with 
a synthetic membrane (e.g. nylon) and previously processed 
animal skin samples, respectively.
Recent Works on TS Formulations
Lopinavir is used in the treatment for HIV infection. When 
taken orally, it has poor bioavailability (~20%) because of its 
low aqueous solubility (0.01 mg/ml), poor dissolution rate, 
and high first-pass metabolism by cytochrome P450 3A4 and 
P450 3A5 isoenzymes [38]. Oral administration of this anti HIV 
agent is also associated with several side effects such as head-
ache, tiredness, weakness and gastrointestinal symptoms; 
diarrhea, mild stomach pain or upset, vomiting and nausea. 
Patel et al. [16] fabricated an user friendly MDTS of lopina-
vir with Kollidon® VA 64 (FFP) and isopropyl myristate (PE). Ex 
vivo skin permeation and skin deposition studies performed 
on microporated pig ear skins resulted a significant increase 
in steady state transdermal flux compared to the plain drug 
solution and the formulation was found to be non-irritating to 
the skin. In vivo study in male Wistar rats gave higher bioavail-
ability (almost three folds) compared to the oral route. 
Nawaz et al. [39] fabricated a TS formulation Eezpain with a 
mixture of herbal components (gaultheria oil, eucalyptus oil, 
turpentine oil, clove oil, menthol and camphor) that posses 
clinically proven analgesic and anti-inflammatory activity. A 
combination of propylene glycol, polyethylene glycol (PEG) 
400, IPA, tween 20, and benzyl alcohol was used to incorpo-
rate other formulation excipients. Applied on 20 human sub-
jects within an age group of 30 to 65 under a prospective, 
open and non-comparative clinical trial set up, this spray for-
mulation resulted significant improve to the patients suffering 
from various forms of pain.
Paradkar et al. [34] developed a TS formulation of clotrima-
zole for its antifungal efficacy up to 12 hours with reduced fre-
quency. This antifungal drug is poorly soluble in water and its 
absorption from the GIT is erratic. It also suffers from various 
adverse effects like abnormal liver function, nausea, vomit-
ing, mild burning, and irritation after its oral administration. 
To avoid all these adverse effects, alternative TS formulation 
is quite rational approach for delivery of this drug [34]. The 
developed formulation had compositions of propylene glycol 
(PG) and polyethylene glycol 400 (PEG 400) as plasticizer and 
solubilizer, various grades of eudragit and ethyl cellulose as 
film forming polymer, different ratios of ethanol and acetone 
as volatile solvent. The developed formulations were charac-
terized by viscosity, drying time, stickiness, appearance and 
integrity of skin and water washability, in vitro drug release, 
spray pattern and spray angle. Ethanol and acetone at 80:20 
ratio together with camphor and menthol (1:1) as PE satisfied 
the desired criteria of TS formulation with a maximum skin 
transport of the drug and improved antifungal efficacy.
Helal and Lane [40] reviewed various published research 
works on the possibilities of transdermal formulation for the 
drugs of angiotensin converting enzyme (ACE) inhibitors (e.g 
captopril, enalapril maleate, lisinopril dihydrate, perindopril 
erbumine, and trandolapril) to avoid their first pass metab-
olisms, increase patients’ compliance and maintenance of a 
constant plasma drug concentration for a prolong duration. 
This review revealed that captopril cannot be explored as 
transdermal formulation due to its large dose (80 mg) and 
skin irritation property. However, perindopril erbumine, and 
trandolapril were described as suitable molecules for this al-
ternative dosage form compared to their available tablet and 
capsule forms.
Desai et al. [41] compared local anesthetic action of lido-
caine during dressing change between two topical formula-
tions: Nopayne®, a lecithin and soybean oil based oil-in-water 
miniemulsion containing 3% lidocaine and Xylocaine® (Astra 
Zeneca), a 4% lidocaine as a lidocaine aqueous solution. A 
double-blind randomized controlled, pilot trial conducted on 
29 patients who were undergoing split thickness skin graft sur-
gery. Both treatments were found equally effective in manag-
ing the procedural pain related to the dressing change. How-
ever, the emulsion formulation showed a tendency towards 
a better outcome for pain relief for a longer duration with 
smaller lidocaine dosage required leading to lower plasma 
concentrations. This study proved selection of an appropriate 
solvent system on the efficacy of TS formulations.
Brown et al. [42] reported comparable efficacy of terbinafine 
topical spray with added patient compliance against com-
mercially available topical solution for Tinea pedis dermato-
phyte infection. This randomized, observer-blind, comparative 
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study was conducted on 120 patients under Phase IIa clini-
cal trial. The rate of mycological cure after one week of once 
daily treatment with equivalent to 20 mg of drug per foot was 
found to be statistically equivalent. However, TS formulation 
reduces the chance of contamination or transfer of organism 
as compared to the topical solution. 
Modified transport fluconazole TS formulation was reported 
by Gohel and Nagori [27] for the treatment of tinea infection. 
Ethyl cellulose and Eudragit® RS100 were used as FFPs for the 
fabrication of the spray formulation. The formulation had an 
eutectic mixture of camphor and menthol as PE cum volatile 
solvent system to dissolve the formulation composition. The 
optimized and stable formulation provided increased in vitro 
permeation of fluconazole through the shed snake skin with 
drug transport equivalent to its minimum inhibitory concen-
tration (8.0 ± 0.4 μg/ml) in 1 hour study. 
Bakshi et al. [12] developed TS formulation of oxybutynin, an 
antimuscarinic drug, used in the treatment of overactive blad-
der. The drug has significant anticholinergic side effect such as 
dry mouth [43]. The developed TS formulation was reported 
to minimize this side effect [12].
TS Formulation: Market Overview
The total number of TDD approved by US-FDA from 2000 until 
2014 is 39. The majority of them are patches, sprays and emul-
sion to overcome the hepatic first pass metabolism associated 
with oral formulations [44]. Around 49% of the approved TDD 
products are indicated for hormonal therapy followed by anal-
gesic class with 23% occupancy [2]. Oral NSAIDs are associated 
with gastrointestinal adverse effects which sometimes can be 
life threatening with prolonged administration. NSAIDs topical 
formulations are being developed in order to avoid these side 
effects and reduce the health care cost, morbidity and mortal-
ity due to the limitation in using their oral dosage forms [45]. 
 So far, a limited number of TS products are available in the 
market. A few more are in the late stage of the development 
[8]. One of the first transdermal products developed was the 
MDTS Evamist®, which was approved by the FDA in 2007. It is 
indicated for the management of menopause-associated va-
somotor symptoms [44] and has been proven to be able to 
achieve therapeutic levels of estradiol in the subjects stud-
ied [46]. The next product approved was Testagen® to treat 
the low testosterone level in men, in spite of some concerns 
regarding the safety of this product were raised, especially 
regarding the third party exposure [11]. Recuvyra® was ap-
proved at a later stage as a pain reliever indicated for dogs [8]. 
Other molecules that have been approved as TS formulations 
for commercial use are estrone, testosterone, hydrocortisone 
aceponate, and lidocaine [9,41]. MedSpray®, a propellant 
based topic spray formulation of terbinafine for Tinea pedis 
dermatophyte infection is under Phase IIa clinical trial [42].
Limitation of TS Formulation
The stratum corneum has been recognized as the main barrier 
in TDD. Due to this barrier property, the ranges of selections of 
drugs are limited; small molecular weight, moderate lipophi-
licity and good solubility both in water and oil compartment 
[7,8]. Despite of the high demand of TDD in numerous con-
ditions such as angina, hypertension, motion sickness, smok-
ing cessation and hormone deficiency, the number of drugs 
intended for TDD specifically in TS form is limited [47]. TS 
formulations are not suitable for drugs with large doses due 
to the limited diffusivity of the skin. The review of the trans-
dermal activity of angiotensin converting enzyme (ACE) inhibi-
tors by Helal and Lane [40]. Stated that the physicochemical 
properties of captopril is not appropriate for transdermal de-
livery compared to other drugs such as enalapril maleate and 
lisinopril dehydrate. This is due to the large dose of the drug 
as the skin can only accommodate 10-20mg dose only. Since 
captopril can cause irritation when taken orally, the reaction 
can be much worse when formulated as TDD system. The only 
solution for captopril to be formulated as TS is by adding anti-
irritant into the formulation. However, there must be an ex-
tensive study done to confirm this theory [40]. 
Apart from the advantages of TS formulation mentioned ear-
lier from the patients’ perspective, it is also a lucrative busi-
ness from the manufacturers’ point of view. This is because of 
their low cost of manufacturing and developing the formula-
tions [7]. However, TS system faces a major problem due to its 
mechanism of passive diffusion for drug transport. The only 
assistance can be the use of chemical penetration enhanc-
ers to increase the driving force in delivering the drugs into 
the skin [48]. There must be an extensive stability and safety 
studies to be done and the optimization of the formulations 
should be ensured before the commercialization of the prod-
uct. TS is a non-occlusive system which will reduce the skin 
irritation, thus the formulation should focus on reducing or 
improving the skin irritation attributes caused by the drugs 
and their excipients. Apart from the third party exposure, 
particularly in endocrinology indications, safety study should 
be targeted for the products, especially that are used for long 
term indications [49].
CONCLUSION
Drug delivery in TS follows passive diffusion mechanism. 
There are certain criteria such as appropriate aqueous solubil-
ity, lipophilicity, molecular weight, melting point, pH and dose 
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size that a drug must fulfill to exploit full advantage of this 
mechanism as these criteria are critical to ensure the delivery 
of the drug across the SC and to achieve the desired therapeu-
tic effect. Due to this reason, there are only a limited number 
of drugs that can be developed as TS formulations. In order to 
enhance the transdermal flux, chemical penetration enhanc-
ers such as propylene glycol, isopropyl myristate, lauryl lactate 
and azone have been introduced into the formulations. They 
act by disrupting the SC layer to provide the pathway for the 
drugs or by increasing their partitioning into the skin. Volatile 
solvent present in the TS formulation also contributes to the 
permeation of drugs through evaporation mechanism. As the 
solvent evaporates, the thermodynamic activity of the drug is 
increased and the flux across the SC is enhanced. Last but not 
least, film-forming polymer (FFP) exerts its effect on the for-
mulation through occlusion mechanism. The results from add-
ing FFPs are varied depending on drugs, not all observe a rise 
in the drug permeation level. There is a need to do a further 
study whether the decline of the drug level is due to the in-
compatibility of FFPs with the drugs or skin or other excipients 
to optimize the TS formulations. In conclusion, the TS formu-
lations need to be further developed and studied extensively 
to overcome the SC barrier. Although the path is challenging, 
but TS formulations have a wide scope to attain a high level of 
user compliance and therapeutic efficacy.
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